Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases

NCT ID: NCT07117435

Last Updated: 2025-08-12

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-05-13
• Study Completion Date: 2026-06-01

Brief Summary

This is a phase Ib/III, randomized, multicenter study evaluating the efficacy and safety of hepatic arterial infusion of paclitaxel cationic liposome in combination with systemic therapy (Oxaliplatin, Capecitabine, with or without Bevacizumab) as first-line treatment in colorectal liver metastases.

Detailed Description

This study includes 2 parts. In Phase Ib part of this study, paclitaxel cationic liposome was administered via hepatic arterial infusion on Day 15 of each 3-week cycle, and in a gradual increment dose from the low-level to the high-level, with the first cycle (21 days) being the DLT observation period. In the Phase III part of this study, participants will be randomized in 1:1 ratio to receive either hepatic arterial infusion of paclitaxel cationic liposome (at the dose to be determined in the Phase Ib) in combination with systemic therapy or systemic therapy.

The primary purpose of the Phase Ib part of this study is to determine the recommended Phase III dose (RP3D) of paclitaxel cationic liposome administered via hepatic arterial infusion on Day 15 of each 3-week cycle.

The primary purpose of the Phase III part of this study is to measure the efficacy and safety of hepatic arterial infusion of paclitaxel cationic liposome in combination with systemic therapy (Oxaliplatin, Capecitabine, with or without Bevacizumab) as first-line treatment in colorectal liver metastases.

Conditions

Colorectal Liver Metastases; First-line Treatment

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental arm

Paclitaxel cationic liposome was administered via hepatic arterial infusion on Day 15 of each 3-week cycle, and in a gradual increment dose range from 33 mg/m\^2 to 55 mg/m\^2, combined with systemic therapy (Oxaliplatin, Capecitabine, with or without Bevacizumab)

Group Type: EXPERIMENTAL

paclitaxel cationic liposome for injection

Intervention Type: DRUG

Paclitaxel cationic liposome was administered through hepatic arterial catheter infusion, in a gradual increment dose range from 33 mg/m\^2 to 55 mg/m\^2

Oxaliplatin

Intervention Type: DRUG

Oxaliplatin 130 mg/m2 i.v. on D1

Capecitabine

Intervention Type: DRUG

Capecitabine 1000 mg/m2 p.o. Bid on Day 1-14

Bevacizumab

Intervention Type: DRUG

Bevacizumab 7.5 mg/kg i.v. on D1

Interventions

paclitaxel cationic liposome for injection

Paclitaxel cationic liposome was administered through hepatic arterial catheter infusion, in a gradual increment dose range from 33 mg/m\^2 to 55 mg/m\^2

Intervention Type: DRUG

Oxaliplatin

Oxaliplatin 130 mg/m2 i.v. on D1

Intervention Type: DRUG

Capecitabine

Capecitabine 1000 mg/m2 p.o. Bid on Day 1-14

Intervention Type: DRUG

Bevacizumab

Bevacizumab 7.5 mg/kg i.v. on D1

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 1. Age range: 18 - 75 years old (inclusive), gender not limited.
• 2. For patients with colorectal liver metastases have been histologically or cytologically confirmed and who are assessed by multidisciplinary team (MDT) to be inoperable for radical surgical resection:

1. Have not received systemic treatment for the metastatic or recurrent disease;

2. For patients who have received neoadjuvant/adjuvant therapy before, the time interval between the last administration and disease progression must be ≥ 6 months;

3. Allow patients who have received local treatment and progressed.

• 3. According to RECIST v1.1, at least one measurable lesion in the hepatic arterial infusion area (long diameter ≥ 1 cm and no previous local treatment).
• 4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
• 5. Life expectancy of at least 3 months.
• 6. Adequate organ function, with laboratory tests meeting the following criteria (no blood transfusion or hematopoietic growth factors within 14 days)
• 7. Fertile patients (male and female) must agree to use reliable contraceptive methods (hormonal contraceptives, barrier methods, or abstinence) with their partners during the study and for at least 6 months after the last dose of study intervention. Women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment.
• 8. Fully understand the clinical study and voluntarily sign a written informed consent form.

Exclusion Criteria

• 1. Patients known to have microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR), and have been evaluated by the investigators to be eligible for immune checkpoint inhibitor therapy.
• 2. Patients known to have wild-type RAS and BRAF, and have been evaluated by the investigators to be eligible for anti-epidermal growth factor receptor (EGFR) drug therapy.
• 3. Unresolved adverse reactions from previous anti-tumor treatments not yet recovered to CTCAE 5.0 grade ≤ 1 (except for alopecia or other toxicities deemed non-risky by the investigators).
• 4. Central nervous system metastasis with clinical symptoms, or meningeal metastasis, or there are other evidences indicating that the patient's central nervous system metastasis or meningeal metastatic lesions have not been controlled, and the investigators judges that the patient is not suitable for enrollment.
• 5. Patients with contraindications for transcatheter arterial infusion.
• 6. Patients with active infections within 2 weeks prior to administration (NCI CTC AE v5.0 ≥ grade 2) (Defined as requiring intravenous administration of antibacterial, antifungal or antiviral drugs for treatment).
• 7. Patients with grade 2 or above peripheral neuropathy (NCI CTC AE v5.0).
• 8. Patients with a history of autoimmune diseases, immunodeficiency disorders, including HIV positive test results, or suffering from other acquired or congenital immune deficiencies, or those currently using immunosuppressive agents.
• 9. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive with HBV DNA ≥ 2×103 IU/mL (can use continuous antiviral treatment); or anti-hepatitis C virus antibody (HCV-Ab) positive with HCV RNA above the measurable limit; or active syphilis.
• 10. Patients with known contraindications to capecitabine or oxaliplatin, paclitaxel or cationic liposome, or have severe allergic reactions; note: If the subject has contraindications to bevacizumab or has severe allergic reactions to any component of bevacizumab, it will not affect the enrollment but should not use bevacizumab in the study, and the specific reasons need to be recorded.
• 11. Patients need to receive strong inducers and strong inhibitors of CYP2C8 and CYP3A4 within 2 weeks before the first study treatment or during the treatment.
• 12. Patients had or have non-infectious pneumonia/interstitial lung disease that requires systemic glucocorticoid treatment.
• 13. Severe cardiovascular disease history, including but not limited to:

• Long QT syndrome;
• High-degree atrioventricular block;
• Severe arrhythmia that is not well controlled by medication;
• Chronic heart failure history and NYHA cardiac function classification ≥ 3;
• Severe valvular regurgitation or stenosis that requires treatment;
• Acute coronary syndrome or severe myocardial disease within 6 months before screening;
• Uncontrolled hypertension;
• Echocardiography suggests LVEF < 50%;
• 14. Patients with a previous history of severe neurological or mental disorders (including epilepsy or dementia) lead to compliance issues.
• 15. Patients with ultrasound-detected limb vascular thrombosis with potentially serious consequences during screening, or who with thromboembolic events within 3 months prior to enrollment.
• 16. Patients with a history of severe bleeding, or who experienced major bleeding events such as intracranial hemorrhage, gastrointestinal bleeding, or purpura within the last 3 months.
• 17. Any other reasons deemed by the investigators.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

The First Affiliated Hospital of Sun Yat-sen University，Lishui Central Hospital

Lishui, Zhejiang, China

Site Status: RECRUITING

Countries

China

Central Contacts

Clinical Trials Information Group officer

Role: CONTACT

ctr-contact@cspc.cn

86-0311-69085587

Facility Contacts

Jiansong Ji, Doctor of Meicine

Role: primary

jjstcty@sina.com

86-13857088508

Other Identifiers

HA131-004

Identifier Type: -

Identifier Source: org_study_id